DrugPatentWatch Database Preview
BRISDELLE Drug Profile
When do Brisdelle patents expire, and when can generic versions of Brisdelle launch?
Brisdelle is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-eight patent family members in thirty-five countries.
The generic ingredient in BRISDELLE is paroxetine mesylate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
Summary for BRISDELLE
| International Patents: | 78 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 10 |
| Clinical Trials: | 4 |
| Patent Applications: | 80 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for BRISDELLE |
| Drug Sales Revenues: | Drug sales revenues for BRISDELLE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BRISDELLE |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for BRISDELLE |
| DailyMed Link: | BRISDELLE at DailyMed |
Pharmacology for BRISDELLE
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
Synonyms for BRISDELLE
| (3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate |
| 217797-14-3 |
| AKOS027321054 |
| Brisdelle (TN) |
| CHEMBL1200609 |
| D05375 |
| LDMP |
| M711N184JE |
| Paroxetine Mesilate |
| Paroxetine Mesylate |
| Paroxetine mesylate (USAN) |
| Paroxetine Mesylate [USAN] |
| Paroxetine methanesulphonate |
| Pexeva |
| Pexeva (TN) |
| POT.mes |
| SCHEMBL143905 |
| SHIJTGJXUHTGGZ-RVXRQPKJSA-N |
| UNII-M711N184JE |
US Patents and Regulatory Information for BRISDELLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |
| Sebela Ireland Ltd | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Sebela Ireland Ltd | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for BRISDELLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BRISDELLE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 7.5 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for BRISDELLE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20010013615 | ➤ Sign Up |
| Slovenia | 0994872 | ➤ Sign Up |
| Russian Federation | 2478379 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
